Background The serogroup A conjugate meningococcal vaccine, MenAfriVac, was
introduced in mass vaccination campaigns in December 2010 in Burkina Faso, Mali and …

The introduction and rollout of a meningococcal serogroup A conjugate vaccine,
MenAfriVac, in the African meningitis belt has eliminated serogroup A meningococcal …

Serogroup A meningococcal epidemics have been a recurrent public health problem,
especially in resource-poor countries of Africa. Recently, the administration in mass …

Analysis of meningococcal strains recovered from outbreaks and epidemics in the African
meningitis belt, using molecular methods, has demonstrated for nearly 20 years the …

Background. Study of meningococcal carriage is essential to understanding the
epidemiology of Neisseria meningitidis infection. Methods. Twenty cross-sectional carriage …

Background The conjugate vaccine against serogroup A Neisseria meningitidis (NmA),
MenAfriVac, was first introduced in mass vaccination campaigns of the 1-29-year-olds in …

Abstract Background In 2010–2017, meningococcal serogroup A conjugate vaccine (MACV)
was introduced in 21 African meningitis belt countries. Neisseria meningitidis A epidemics …

The introduction of a new Group A meningococcal conjugate vaccine, MenAfriVacR, has
been a important public health success. Group A meningococcal meningitis has …

Neisseria meningitidis is responsible for the seasonal burden and recurrent epidemics of
meningitis in an area of sub-Saharan Africa known as the meningitis belt. Historically, the …

Objective To undertake a review of the literature on the epidemiology of meningococcal
disease in India, with a view to informing future control policies. Methods We searched the …